RenovoRx, Inc.
RNXTHealthcare|Biotechnology|US
$1.13
-0.06 (-5.04%)
DCF Value
$0.89
Tangible Book / Share
$0.19
Cash / Share
$0.22
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT03257033 Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC | Locally Advanced Pancreatic Cancer | P3 | Active | 190 | RCT, Open-label | Gemcitabine, nab-paclitaxel |
| NCT06805461 PumaRx Registry Trial | Solid Tumors | Recruiting | 1,000 | — | — | |
| NCT02237157 A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer | Pancreatic Cancer | P1 | Completed | 20 | Open-label | Gemcitabine, local delivery |
| NCT02591082 Intra-Arterial Treatment of Pancreatic Cancer Using the RenovoCath™ RC120 Catheter | Pancreatic Neoplasms | Completed | 25 | — | — |